SCHEMBL6353030

SCHEMBL6353030

CC(O)ONCCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8501614 0.79
SCHEMBL14008328 0.78
SCHEMBL27854452 0.71
SCHEMBL2058388 0.70
SCHEMBL28800803 0.69 GABRR1 (0.35)
Isopropyl Alcohol SCHEMBL11146748 0.67 CA12 (0.62)
SCHEMBL17472963 0.67 CA12 (0.62)
SCHEMBL10594176 0.67 GABRR1 (0.30)
SCHEMBL28034763 0.67 CA12 (0.50)
SCHEMBL11738050 0.66 CA12 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936593-B1 Method of down-regulating gene expression HYBRIDON, INC. (US) 2005-08-30 US disclosed
US-20040033980-A1 Method of down-regulating gene expression HYBRIDON, INC. 2004-02-19 US disclosed
US-6645943-B1 Method of down-regulating gene expression HYBRIDON, INC. 2003-11-11 US disclosed
US-6608035-B1 Orally administering to mammal oligonucleotide of 15 to 30 nucleotides, comprising phosphorothioate linkages between nucleosides and 2'-O-alkoxyalkyl-ribonucleotides at each end, whereby oligonucleotide is intact in liver and kidney tissue HYBRIDON, INC. 2003-08-19 US disclosed